GemPharmatech vs Selvita

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/gempharmatech/selvita

Category	GemPharmatech	Selvita
Listed site	cro	cro
Summary	GemPharmatech develops and supplies genetically engineered mouse models (GEMMs) and preclinical research services using CRISPR/Cas9 and gene-editing technologies, with a library of 25,000+ mouse strains including KO/cKO, humanized, and immunodeficient models.	Selvita is an integrated drug discovery and development service provider offering comprehensive solutions from target validation through preclinical candidate nomination and clinical manufacturing, with expertise in small molecules, antibodies, and protein degraders.
Services	Specialized & Large-Animal Models In Vivo PK / PD Studies In Vivo Efficacy Models Preclinical In Vivo Studies In Vitro Pharmacology Preclinical In Vitro Studies Target Identification & Validation	Bioinformatics & Data Science Computational & In-Silico Drug Discovery Medicinal Chemistry High-Throughput Screening Target Identification & Validation Discovery Research In Vitro Pharmacology In Vitro ADME / DMPK Preclinical In Vitro Studies In Vivo PK / PD Studies In Vivo Efficacy Models Preclinical In Vivo Studies Analytical Method Development & Validation ICH Stability Studies Regulatory Affairs Bioanalysis LC-MS Bioanalysis (Small Molecule) Protein Engineering Microbiology Services
Modalities	Biologics (Monoclonal Antibodies)	Small Molecule Biologics (Monoclonal Antibodies) Peptide
Indications	Oncology Immunology Neurology Metabolic Cardiovascular Infectious Disease Rare Disease	Oncology Respiratory Neurology Metabolic Infectious Disease Gastroenterology Immunology
Locations	Headquarters, Jiangsu, China	Data not yet provided.
Certifications	Data not yet provided.	Data not yet provided.
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.